Clinical Trials Browser

Phase 1/2 × Unknown × Imatinib Mesylate × Clear all

NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Phase 1/2 Unknown

Melanoma

NCT04138381 2023-03-27

SeliGIST

Phase 1/2 Unknown

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT00028847 2013-09-17

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Phase 1/2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase